Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation

NCT06137378 is registered in ClinicalTrials.gov with University of Leipzig as lead sponsor.

NCT NCT06137378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06137378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation
Lead sponsor
University of Leipzig
Phase
Phase 2
Overall status
Recruiting
Start date
April 17, 2024
Completion date
December 31, 2030
Enrollment
140 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hypopharyngeal squamous cell carcinoma, laryngeal cancer, laryngeal neoplasms, laryngeal squamous cell carcinoma, laryngeal squamous cell carcinoma stage iii, laryngeal squamous cell carcinoma stage iv, laryngectomy; status, squamous cell carcinoma of head and neck, squamous cell carcinoma of larynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the larynx stage iii, squamous cell carcinoma of the larynx stage iv